Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.
An article from
News roundup
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.
Published Aug. 28, 2026
Getty Images
Moderna shares surged after positive Phase 3 results for its Merck-partnered melanoma cancer vaccine, boosting confidence in its…
Moderna Shares More Than Double on Success of mRNA Cancer Vaccine
The results come at a pivotal moment for Moderna and mRNA research.
Moderna plans a $2B convertible note offering; AstraZeneca-Amgen's Tezspire and Biokin's ADC post Phase 3 wins; Takeda exits…
Moderna Shares More Than Double on Success of mRNA Cancer Vaccine
Moderna Shares More Than Double on Success of mRNA Cancer Vaccine
Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins
Moderna raises $2 billion in convertible notes for cancer vaccine
Moderna Borrows $2 Billion To Expand Oncology Business - Moderna (NASDAQ:MRNA)
What’s in Merck and Moderna’s cancer vaccine algorithm?
Inside Moderna and Merck’s cancer vaccine triumph
Health Care Up as Biotech Momentum Persists — Health Care Roundup
Hype for Moderna’s cancer vaccine is running ahead of the math
